These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35172633)

  • 21. [Clinical research progression of molecular-targeted drugs and PD-1 inhibitors for advanced hepatocellular carcinoma].
    Lai JM; Hu S; Lin H; Luo H; Luo YB
    Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):406-409. PubMed ID: 31216824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.
    Greten TF; Lai CW; Li G; Staveley-O'Carroll KF
    Gastroenterology; 2019 Jan; 156(2):510-524. PubMed ID: 30287171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.
    Liu G; Zhou W; Li X; Guo L; He T; Zhao J; Gong L
    Front Immunol; 2021; 12():712351. PubMed ID: 34504494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of tumor-associated regulatory T cell deletion and PD-1/PD-L1 blockade: A promising immunotherapy for hepatocellular carcinoma?
    Yang HY; Sun LJ; Mao YL
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):93-94. PubMed ID: 29576280
    [No Abstract]   [Full Text] [Related]  

  • 25. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications.
    Sun X; Zhang Q; Mei J; Yang Z; Chen M; Liang T
    BMC Cancer; 2022 Mar; 22(1):293. PubMed ID: 35305593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
    Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
    Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.
    Moreno-Cubero E; Larrubia JR
    World J Gastroenterol; 2016 Jul; 22(28):6469-83. PubMed ID: 27605882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma.
    Di Blasi D; Boldanova T; Mori L; Terracciano L; Heim MH; De Libero G
    Cell Mol Gastroenterol Hepatol; 2020; 9(2):195-218. PubMed ID: 31445190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma.
    Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Xu HF; Gao QZ; Yang RJ
    Immunotherapy; 2021 Dec; 13(17):1395-1405. PubMed ID: 34607482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Programmed cell death protein 1 (PD-1)-inhibition in hepatocellular carcinoma (HCC): a single center experience.
    Mahn R; Vogt A; Kupczyk P; Sadeghlar F; van Beekum K; Hüneburg R; Meyer C; Toma M; Ahmadzadehfar H; Essler M; Matthaei H; Lingohr P; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
    Scand J Gastroenterol; 2020 Sep; 55(9):1057-1062. PubMed ID: 32692941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nivolumab for the treatment of hepatocellular carcinoma.
    Finkelmeier F; Waidmann O; Trojan J
    Expert Rev Anticancer Ther; 2018 Dec; 18(12):1169-1175. PubMed ID: 30304963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical application of camrelizumab on advanced hepatocellular carcinoma.
    Chen Z; Lu X; Koral K
    Expert Rev Gastroenterol Hepatol; 2020 Nov; 14(11):1017-1024. PubMed ID: 32762583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mouse Models of Oncoimmunology in Hepatocellular Carcinoma.
    Bresnahan E; Lindblad KE; Ruiz de Galarreta M; Lujambio A
    Clin Cancer Res; 2020 Oct; 26(20):5276-5286. PubMed ID: 32327473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
    Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
    J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma.
    Wehrenberg-Klee E; Goyal L; Dugan M; Zhu AX; Ganguli S
    Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1799-1802. PubMed ID: 29845347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma.
    Kuo HY; Han MZ; Liao CH; Lin YJ; Wang CT; Chen SH; Chang TT; Chen PJ; Lin SH; Chen CY; Chuang CH; Wu IC; Wu JS; Hong TC; Hsieh MT; Lee YC; Wu HT; Tsai HM
    Pharmaceutics; 2022 Oct; 14(11):. PubMed ID: 36365082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.
    Feun LG; Li YY; Wu C; Wangpaichitr M; Jones PD; Richman SP; Madrazo B; Kwon D; Garcia-Buitrago M; Martin P; Hosein PJ; Savaraj N
    Cancer; 2019 Oct; 125(20):3603-3614. PubMed ID: 31251403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study.
    Fessas P; Kaseb A; Wang Y; Saeed A; Szafron D; Jun T; Dharmapuri S; Rafeh Naqash A; Muzaffar M; Navaid M; Khan U; Lee C; Bulumulle A; Yu B; Paul S; Nimkar N; Bettinger D; Benevento F; Hildebrand H; Pressiani T; Abugabal YI; Personeni N; Huang YH; Rimassa L; Ang C; Marron T; Pinato DJ
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Anti-Programmed Cell Death Protein-1 Immunotherapy for Advanced Hepatocellular Carcinoma With Pulmonary Metastases: A Single-Center, Retrospective Study.
    Zhao M; Zhang Y; Wang H; Liu P; Da J; Du Y
    Technol Cancer Res Treat; 2021; 20():15330338211038114. PubMed ID: 34525851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nivolumab for the treatment of hepatocellular carcinoma.
    Chiew Woon L; Joycelyn Jie Xin L; Su Pin C
    Expert Opin Biol Ther; 2020 Jul; 20(7):687-693. PubMed ID: 32249635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.